MS/AL Radiation Oncology Research Partnership

MS/AL 放射肿瘤学研究合作伙伴关系

• 批准号: 7932842
• 负责人: William David Burleson
• 金额: $ 50.51万
• 依托单位: SINGING RIVER HEALTH SYSTEM
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-15 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7932842
• 关键词: African American; Alabama; Award; Breast; Cancer Center; Cancer Control; Cancer Patient; Caring; Clinical; Clinical Research; Clinical Trials; Collaborations; Colorectal; Communities; Community Healthcare; Community Outreach; Development; Diagnosis; Early Diagnosis; Elderly; Ensure; Funding; Goals; Government; Grant; Healthcare; Healthcare Systems; Hospitals; Lung; Malignant Neoplasms; Medical Staff; Medical center; Medicine; Minority Groups; Mission; Mississippi; Outcome; Patients; Prevention; Progress Reports; Prostate; Radiation Oncology; Recurrent Malignant Neoplasm; Research; Research Activity; Research Infrastructure; Research Personnel; Rest; Rivers; Services; Site; Social Work; Staging; System; Transportation; Underinsured; Underrepresented Minority; Underserved Population; Uninsured; United States National Institutes of Health; Universities; health disparity; improved; patient population; programs; public health relevance; treatment trial

DESCRIPTION (provided by applicant): In 2003, Singing River Hospital System (SRHS) was awarded a 5-year NIH grant which allowed SRHS to build infrastructure and establish a clinical research program aimed at reducing barriers to clinical research for minorities and the underserved. This project will continue the efforts begun with that grant. SRHS will maintain partnerships with the University of Alabama at Birmingham and the University of Mississippi Medical Center. These collaborations provide access to NCI sponsored clinical research trials to cancer patients receiving care at SRHS. The clinical research opportunities available for the cancer patients include prevention studies and treatment trials for common cancers such as breast, lung, prostate and colorectal. SRHS also offers trials for patients facing treatment challenges such as late stage diagnosis, recurrent cancers and those with limited treatment options. More than 76 clinical trials have been opened at SRHS with more than 102 patients accrued to studies during the CDRP grant. NCI funding also provides our hospital system the opportunity to offer our patients services such as transportation, social services and educational programming. These services are benefiting the Singing River Hospital System patients as well as the community at large and national health care. The RCC medical staff provided availability of clinical research at the community level making it integral to the mission of the cancer center. Grant investigators and staff recognize the importance of clinical research and are taking steps to ensure the sustainability of the research office. During this project SRHS will strengthen its clinical research activities while lessening its need for government funding. There are five sustainability options fully detailed in the research plan. They are: 1) Development of the Coastal Research Consortium; 2) Internal Funding; 3) Expansion of clinical research to a system-wide department; 4) Collaboration with UMMC as a community clinical affiliate; and 5) pursue CCOP/MB-CCOP funding with other CDRP sites. PUBLIC HEALTH RELEVANCE: Clinical research is essential to improving healthcare for the public. Our project brings clinical trials to a local hospital setting allowing patients who would not normally have access to cutting-edge medicine the opportunity to participate in clinical trials. As one SRHS clinical trial patient said, "lt was convenient for me to use this cancer center but when I found out about the clinical trials, it made me want to stay here even longer".

描述（由申请人提供）： 2003年，Singing River医院系统（SRHS）获得了一项为期5年的NIH赠款，使SRHS能够建立基础设施，并建立一个临床研究计划，旨在减少少数民族和服务不足人群的临床研究障碍。该项目将继续开展从该赠款开始的努力。SRHS将与伯明翰的亚拉巴马大学和密西西比大学医学中心保持合作关系。这些合作为在SRHS接受治疗的癌症患者提供了NCI赞助的临床研究试验。为癌症患者提供的临床研究机会包括针对常见癌症（如乳腺癌、肺癌、前列腺癌和结直肠癌）的预防研究和治疗试验。SRHS还为面临治疗挑战的患者提供试验，如晚期诊断，复发性癌症和治疗选择有限的患者。在SRHS已经开展了超过76项临床试验，在CDRP资助期间有超过102名患者参加了研究。NCI的资金还为我们的医院系统提供了机会，为我们的病人提供服务，如交通，社会服务和教育计划。这些服务使辛格河医院系统的病人以及整个社区和国家保健受益。RCC医务人员在社区一级提供临床研究，使其成为癌症中心使命的组成部分。格兰特研究人员和工作人员认识到临床研究的重要性，并正在采取措施，以确保研究办公室的可持续性。在该项目期间，SRHS将加强其临床研究活动，同时减少对政府资金的需求。研究计划中详细列出了五个可持续发展方案。它们是：1）沿海研究联盟的发展; 2）内部资金; 3）临床研究扩展到全系统的部门; 4）与UMMC合作，作为社区临床附属机构; 5）与其他CDRP站点一起寻求CCOP/MB-CCOP资金。 公共卫生相关性： 临床研究对于改善公众的医疗保健至关重要。我们的项目将临床试验带到当地医院，让通常无法获得尖端药物的患者有机会参与临床试验。正如一位SRHS临床试验患者所说，“使用这个癌症中心对我来说很方便，但当我发现临床试验时，它让我想在这里呆得更久”。